金沙(8888js-官方JS认证)-Made in China

Be the most trusted biotech company

2020-02-19

Henlius Appointed Mr. Wenjie Zhang as President of the Company, Moving Towards a New Phase of Overall Commercial Operation
2020-02-18

Henlius Successfully Held Its Fourth Scientific Advisory Board (SAB) Meeting
2020-01-21

Henlius Anti-HER2 Domain II Monoclonal Antibody HLX11 Received Clinical Approval from NMPA
2020-01-10

Henlius Anti-CTLA-4 Monoclonal Antibody HLX13 Received IND Application Acceptance Notification from NMPA
2019-12-31

First Patient Dosed in Phase 2 Study of Henlius Innovative Anti-PD-1 Monoclonal Antibody HLX10 for the Treatment of Chronic Hepatitis B
2019-12-13

First Patient Dosed in Phase 3 Clinical Trial of Anti-PD-1 mAb HLX10 in Combination with Bevacizumab Biosimilar HLX04 in Patients with Metastatic nsNSCLC
2019-12-13

First Patient Dosed in Phase 3 Study of Anti-PD-1 mAb in Combination with Chemotherapy in Neo-/Adjuvant Treatment for Patients with Gastric Cancer
2019-12-09

The Anti-PD-1 mAb Combined with Anti-EGFR mAb Therapy of Henlius Received Approvals to Conduct Clinical Trials by NMPA
2019-12-09

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 DLBCL Study